119,038 Shares in REGENXBIO Inc. $RGNX Purchased by Royce & Associates LP

Royce & Associates LP acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 119,038 shares of the biotechnology company’s stock, valued at approximately $1,714,000.

Several other hedge funds have also recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new position in shares of REGENXBIO in the 3rd quarter valued at approximately $37,000. Jones Financial Companies Lllp boosted its position in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares in the last quarter. Captrust Financial Advisors bought a new position in REGENXBIO in the second quarter valued at approximately $85,000. Prudential Financial Inc. bought a new position in REGENXBIO in the second quarter valued at approximately $87,000. Finally, ProShare Advisors LLC acquired a new position in REGENXBIO during the fourth quarter valued at approximately $155,000. 88.08% of the stock is owned by institutional investors.

Insider Buying and Selling at REGENXBIO

In related news, insider Steve Pakola sold 15,309 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18. Following the sale, the insider owned 232,617 shares in the company, valued at $2,563,439.34. The trade was a 6.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.22% of the stock is currently owned by company insiders.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $7.01 on Friday. REGENXBIO Inc. has a one year low of $5.45 and a one year high of $16.19. The company has a market cap of $362.42 million, a price-to-earnings ratio of -1.25 and a beta of 1.12. The firm has a 50 day simple moving average of $8.32 and a 200 day simple moving average of $10.58.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The company had revenue of $6.39 million for the quarter, compared to the consensus estimate of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. As a group, analysts expect that REGENXBIO Inc. will post -3.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RGNX. HC Wainwright cut their target price on REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Morgan Stanley set a $16.00 price target on REGENXBIO in a report on Friday, May 15th. Wall Street Zen downgraded REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Robert W. Baird set a $27.00 price objective on REGENXBIO in a research note on Tuesday, February 10th. Finally, Bank of America decreased their target price on REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.91.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.